Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CT103A |
Synonyms | |
Therapy Description |
CT103A are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting the B-cell maturation antigen (BCMA) and containing TNFRSF9 (4-1BB) costimulatory and CD3zeta activation domains, which may have antitumor activity (PMID: 33512480). |